News Articles

New Data Show High Adherence Rates with Pradaxa® (dabigatran etexilate) in NVAF Patients INGELHEIM, Germany -Monday 5 December 2016  

New analysis of GLORIA™-AF Registry Program includes data from nearly 3,000 patients across the world1 Data presented at the American Society of Hematology (ASH) Annual Meeting1 (BUSINESS WIRE)-- Boehringer Ingelheim today announced results from a new analysis of the...

Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches for hearing loss -Monday 28 November 2016  

  360 million people worldwide suffer from disabling hearing loss with no effective treatment available New collaboration with China Southeast University is part of the Research Beyond Borders (RBB) initiative, which aims to explore emerging science within and beyond Boehringer...

Jardiance® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes... -Monday 14 November 2016  

(BUSINESS WIRE)-- New data presented at the American Heart Association Scientific Sessions 2016 showed that Jardiance® (empagliflozin) consistently reduced the risk for cardiovascular death, regardless of the type of cardiovascular disease at baseline, compared with placebo when added to...

Boehringer Ingelheim’s adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in... -Wednesday 26 October 2016

Phase III study established equivalence in efficacy and similar safety profile between BI 695501 and Humira® (adalimumab) in patients with active rheumatoid arthritis (RA) Results pave the way for submitting BI 695501 for regulatory approval in key markets (BUSINESS WIRE)--...

Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology... -Thursday 29 September 2016  

(BUSINESS WIRE)-- Boehringer Ingelheim and Sarah Cannon Research Institute, the research arm of Sarah Cannon, the global cancer institute of HCA, announced today a new strategic collaboration. This partnership brings together Boehringer Ingelheim’s extensive experience in cancer drug...

New survey reveals 9 out of 10 patients with IPF were happy with how their doctor told them about their IPF diagnosis -Tuesday 20 September 2016  

However, need for additional information to help patients at IPF diagnosis identified Survey also revealed that physicians’ understanding of their patients’ priorities were aligned with patients' actual priorities at diagnosis (BUSINESS WIRE)-- A diagnosis of IPF is news...

Glyxambi® (empagliflozin/linagliptin) approval recommended by CHMP for adults with type 2 diabetes in the European... -Saturday 17 September 2016  

(BUSINESS WIRE)-- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of Glyxambi® (empagliflozin/linagliptin) for use in adults with type 2 diabetes (T2D). Glyxambi®, from the Boehringer Ingelheim and Eli Lilly and...

New long-term data demonstrates continued safety and beneficial effect of OFEV® (nintedanib) for patients with IPF -Wednesday 7 September 2016

Interim data suggest long-term benefit with consistent yearly changes in forced vital capacity up to 3 years in patients treated with OFEV® in INPULSIS® and INPULSIS®-ON Long-term treatment up to 51 months had a manageable safety and tolerability profile, with no new safety signals...

Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice -Monday 15 August 2016  

Praxbind® (idarucizumab) is the specific reversal agent for the oral anticoagulant Pradaxa® (dabigatran)1,2 Praxbind® is already available in over 5,000 hospitals worldwide and is approved in over 35 countries3 RE-VECTO will provide insights into the diverse types of situations in...

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer -Wednesday 13 July 2016

• Study to evaluate potential of novel combination therapy for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) • Boehringer Ingelheim’s IGF mAB BI 836845 and Lilly’s CDK 4 and 6 inhibitor abemaciclib have shown...

New Jardiance® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age... -Monday 13 June 2016  

In a separate analysis, Jardiance® also reduced risk for CV events consistently in groups divided by LDL cholesterol level Results from sub-analyses of the landmark EMPA-REG OUTCOME® trial presented at the American Diabetes Association 76th Scientific Sessions® (BUSINESS...

LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the... -Monday 9 May 2016

The trial will evaluate efficacy and safety of nintedanib* as a first-line oral treatment in combination with pemetrexed/cisplatin followed by continuing nintedanib monotherapy Nintedanib targets receptors that play a role in tumour growth and development of metastasis in malignant...

The Lancet Respiratory Medicine: New analysis shows only minority of COPD patients may benefit from inhaled... -Friday 8 April 2016  

• New post-hoc analysis shows routine eosinophil blood test could help identify the small group of severe/very severe patients who may benefit from addition of ICS* • Only 20 percent of patients in WISDOM† study1 benefited from addition of ICS on top of Spiriva®‡ and a...

New Analyses: Adding SPIRIVA® Respimat® Effective for Uncontrolled Asthma – Regardless of Allergy Subtype1,2,3 -Tuesday 8 March 2016  

SPIRIVA® Respimat® shown effective in the broad range of asthma patients studied who continued to experience symptoms despite taking other asthma maintenance therapies4 New analyses show improved lung function5 and asthma symptom control and reduced asthma exacerbations for patients...

AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds -Monday 7 March 2016

AbbVie and Boehringer Ingelheim will share responsibility for future clinical development and establish a Joint Steering Committee Anti-IL-23 antibody now in Phase 3 for psoriasis demonstrated greater efficacy over ustekinumab in Phase 2 clinical studies with a potential for quarterly...

New survey gives voice to people living with a rare and devastating lung disease: “When I think of IPF I think of... -Monday 29 February 2016    

International survey provides unique insights into the emotional truths of living with idiopathic pulmonary fibrosis (IPF) Worry and fear are the most common emotions experienced when diagnosed with IPF Patient support groups make people with IPF feel less isolated and provide access to...

New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations -Thursday 25 February 2016

Pooled data from three key studies confirms that OFEV® slows disease progression by approximately 50% as measured by decline in forced vital capacity (FVC)*1-8 The pooled analysis also demonstrated that OFEV® significantly reduced the risk of acute exacerbations by...

Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site -Wednesday 23 December 2015  

• The total investment is around a half billion euro. • With this investment, Boehringer Ingelheim plans on adding more than 400 jobs. • The biopharmaceutical production plant will go into operation by 2021. (BUSINESS WIRE)-- Boehringer Ingelheim will make a significant investment...

Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site -Tuesday 22 December 2015

• The total investment is around a half billion euro. • With this investment, Boehringer Ingelheim plans on adding more than 400 jobs. • The biopharmaceutical production plant will go into operation by 2021. (BUSINESS WIRE)-- Boehringer Ingelheim will make a significant investment...

Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer -Monday 21 December 2015

         New data from Phase I/II clinical trial presented at ESMO Asia 2015 Congress showcase the potential for BI 1482694* to become a new treatment option for EGFR mutation-positive lung cancer In 62% of patients with T790M-positive NSCLC objective responses were achieved, including...